Literature DB >> 18562626

SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Sam R Holmstrom1, Sergey Chupreta, Alex Yick-Lun So, Jorge A Iñiguez-Lluhí.   

Abstract

Multiple transcription factors, including members of the nuclear receptor family, harbor one or more copies of a short regulatory motif that limits synergistic transactivation in a context-dependent manner. These synergy control (SC) motifs exert their effects by serving as sites for posttranslational modification by small ubiquitin-like modifier (SUMO) proteins. By analyzing the requirements for both synergy control and SUMOylation in the glucocorticoid receptor (GR), we find that an intact ligand-binding domain and an engaged DNA- binding domain dimerization interface are necessary for effective synergy control. However, these features, which promote stable assembly of GR-DNA complexes, are required downstream of SUMOylation because their disruption or deletion does not interfere with SUMO modification. Remarkably, in the absence of these features, sensitivity to the effects of SUMOylation can be restored simply by stabilization of DNA interactions through a heterologous DNA binding domain. The data indicate that stable interaction with DNA is an important prerequisite for SUMO-dependent transcriptional inhibition. Analysis of genomic regions occupied by GR indicates that the effects of SC motif SUMOylation are most evident at multiple, near-ideal GR binding sites and that SUMOylation selectively affects the induction of linked endogenous genes. Although the SUMO-binding protein DAXX has been proposed to mediate the inhibitory effects of GR SUMOylation, we find that inhibition by DAXX is independent of GR SUMOylation. Furthermore, neither expression nor knockdown of DAXX influences SUMO effects on GR. We therefore propose that stable binding of GR to multiple sites on DNA allows for the SUMO-dependent recruitment of inhibitory factors distinct from DAXX.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562626      PMCID: PMC2631372          DOI: 10.1210/me.2007-0581

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  82 in total

1.  Cooperativity and dimerization of recombinant human estrogen receptor hormone-binding domain.

Authors:  M E Brandt; L E Vickery
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

2.  DNA binding of the glucocorticoid receptor is not essential for survival.

Authors:  H M Reichardt; K H Kaestner; J Tuckermann; O Kretz; O Wessely; R Bock; P Gass; W Schmid; P Herrlich; P Angel; G Schütz
Journal:  Cell       Date:  1998-05-15       Impact factor: 41.582

3.  Characterization of a monoclonal antibody to the rat liver glucocorticoid receptor.

Authors:  B Gametchu; R W Harrison
Journal:  Endocrinology       Date:  1984-01       Impact factor: 4.736

4.  Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.

Authors:  Jing Song; Linda K Durrin; Thomas A Wilkinson; Theodore G Krontiris; Yuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-23       Impact factor: 11.205

Review 5.  Genetic dissection of corticosteroid receptor function in mice.

Authors:  T M Wintermantel; S Berger; E F Greiner; G Schütz
Journal:  Horm Metab Res       Date:  2004-06       Impact factor: 2.936

6.  SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1).

Authors:  Wei-Yi Chen; Wen-Chih Lee; Nai-Chi Hsu; Fu Huang; Bon-Chu Chung
Journal:  J Biol Chem       Date:  2004-06-10       Impact factor: 5.157

7.  Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9.

Authors:  Tomoko Komatsu; Hirofumi Mizusaki; Tokuo Mukai; Hidesato Ogawa; Daichi Baba; Masahiro Shirakawa; Shigetsugu Hatakeyama; Keiichi I Nakayama; Hideki Yamamoto; Akira Kikuchi; Ken-ichirou Morohashi
Journal:  Mol Endocrinol       Date:  2004-06-10

8.  Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement.

Authors:  P J Godowski; S Rusconi; R Miesfeld; K R Yamamoto
Journal:  Nature       Date:  1987 Jan 22-28       Impact factor: 49.962

9.  ZNF76, a novel transcriptional repressor targeting TATA-binding protein, is modulated by sumoylation.

Authors:  Gang Zheng; Yu-Chung Yang
Journal:  J Biol Chem       Date:  2004-07-26       Impact factor: 5.157

10.  A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus.

Authors:  Kurt M Bohren; Varsha Nadkarni; Jian H Song; Kenneth H Gabbay; David Owerbach
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

View more
  30 in total

1.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

2.  Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation.

Authors:  Hany Abdel-Hafiz; Michelle L Dudevoir; Kathryn B Horwitz
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

Review 3.  The Roles of SUMO in Metabolic Regulation.

Authors:  Elena Kamynina; Patrick J Stover
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

5.  Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx.

Authors:  Vera Lukashchuk; Roger D Everett
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.

Authors:  Sarmistha Mukherjee; Osvaldo Cruz-Rodríguez; Eric Bolton; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

7.  Role of SUMOylation in full antiestrogenicity.

Authors:  Khalid Hilmi; Nader Hussein; Rodrigo Mendoza-Sanchez; Mohamed El-Ezzy; Houssam Ismail; Chantal Durette; Martine Bail; Maria Johanna Rozendaal; Michel Bouvier; Pierre Thibault; James L Gleason; Sylvie Mader
Journal:  Mol Cell Biol       Date:  2012-07-23       Impact factor: 4.272

8.  GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression.

Authors:  Guoqiang Hua; Laetitia Paulen; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

9.  A SUMO-regulated activation function controls synergy of c-Myb through a repressor-activator switch leading to differential p300 recruitment.

Authors:  Ann-Kristin Molvaersmyr; Thomas Saether; Siv Gilfillan; Petra Isabel Lorenzo; Heidi Kvaløy; Vilborg Matre; Odd Stokke Gabrielsen
Journal:  Nucleic Acids Res       Date:  2010-04-12       Impact factor: 16.971

10.  Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.

Authors:  Sarmistha Mukherjee; Monzy Thomas; Nahid Dadgar; Andrew P Lieberman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.